...
search icon
avtx-img

Avalo Therapeutics Inc, Common Stock

AVTX

NAQ

$6.87

-$0.13

(-1.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$71.89M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.0741
Volume info-icon
This is the total number of shares traded during the most recent trading day.
63.52K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.03
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.95 L
$22.47 H
$6.87

About Avalo Therapeutics Inc, Common Stock

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAVTXSectorS&P500
1-Week Return-13.91%1.76%-2.5%
1-Month Return-25.57%0.33%-3.91%
3-Month Return-26.05%-8.58%-0.59%
6-Month Return-45.69%-4.26%3.45%
1-Year Return44.63%1.27%22.31%
3-Year Return-99.75%5.33%25%
5-Year Return-99.95%38.09%77.23%
10-Year Return-99.94%102.29%188.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue6.75M6.70M5.40M18.05M1.92M[{"date":"2019-12-31","value":37.39,"profit":true},{"date":"2020-12-31","value":37.11,"profit":true},{"date":"2021-12-31","value":29.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":10.66,"profit":true}]
Cost of Revenue11.63M300.00K1.49M3.43M1.28M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.58,"profit":true},{"date":"2021-12-31","value":12.82,"profit":true},{"date":"2022-12-31","value":29.53,"profit":true},{"date":"2023-12-31","value":11.04,"profit":true}]
Gross Profit(4.88M)6.40M3.91M14.62M640.00K[{"date":"2019-12-31","value":-33.38,"profit":false},{"date":"2020-12-31","value":43.78,"profit":true},{"date":"2021-12-31","value":26.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.38,"profit":true}]
Gross Margin(72.29%)95.52%72.38%80.98%33.26%[{"date":"2019-12-31","value":-75.68,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.77,"profit":true},{"date":"2022-12-31","value":84.77,"profit":true},{"date":"2023-12-31","value":34.82,"profit":true}]
Operating Expenses24.71M53.69M86.04M52.06M640.00K[{"date":"2019-12-31","value":28.72,"profit":true},{"date":"2020-12-31","value":62.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":60.5,"profit":true},{"date":"2023-12-31","value":0.74,"profit":true}]
Operating Income(17.39M)(26.95M)(82.13M)(37.44M)(23.44M)[{"date":"2019-12-31","value":-1739400000,"profit":false},{"date":"2020-12-31","value":-2695300000,"profit":false},{"date":"2021-12-31","value":-8213400000,"profit":false},{"date":"2022-12-31","value":-3744000000,"profit":false},{"date":"2023-12-31","value":-2344400000,"profit":false}]
Total Non-Operating Income/Expense1.52M5.71M(4.80M)(8.36M)(12.53M)[{"date":"2019-12-31","value":26.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-84.03,"profit":false},{"date":"2022-12-31","value":-146.28,"profit":false},{"date":"2023-12-31","value":-219.3,"profit":false}]
Pre-Tax Income(15.99M)(67.18M)(84.55M)(41.63M)(31.53M)[{"date":"2019-12-31","value":-1599100000,"profit":false},{"date":"2020-12-31","value":-6717700000,"profit":false},{"date":"2021-12-31","value":-8454500000,"profit":false},{"date":"2022-12-31","value":-4163000000,"profit":false},{"date":"2023-12-31","value":-3153000000,"profit":false}]
Income Taxes280.00K(2.79M)(196.00K)28.00K14.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-997.5,"profit":false},{"date":"2021-12-31","value":-70,"profit":false},{"date":"2022-12-31","value":10,"profit":true},{"date":"2023-12-31","value":5,"profit":true}]
Income After Taxes(16.27M)(64.38M)(84.35M)(41.66M)(31.54M)[{"date":"2019-12-31","value":-1627100000,"profit":false},{"date":"2020-12-31","value":-6438400000,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3154400000,"profit":false}]
Income From Continuous Operations(16.27M)(64.38M)(84.35M)(41.66M)(33.19M)[{"date":"2019-12-31","value":-1627075300,"profit":false},{"date":"2020-12-31","value":-6438310100,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3318800000,"profit":false}]
Income From Discontinued Operations198.21K883.78K(27.00K)--[{"date":"2019-12-31","value":22.43,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3.06,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(16.27M)(64.38M)(84.35M)(41.66M)(31.54M)[{"date":"2019-12-31","value":-1627100000,"profit":false},{"date":"2020-12-31","value":-6438400000,"profit":false},{"date":"2021-12-31","value":-8434900000,"profit":false},{"date":"2022-12-31","value":-4165800000,"profit":false},{"date":"2023-12-31","value":-3154400000,"profit":false}]
EPS (Diluted)(3.36)(10.56)(9.96)(4.48)(117.76)[{"date":"2019-12-31","value":-336,"profit":false},{"date":"2020-12-31","value":-1056,"profit":false},{"date":"2021-12-31","value":-996,"profit":false},{"date":"2022-12-31","value":-448,"profit":false},{"date":"2023-12-31","value":-11776,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AVTX
Cash Ratio 1.35
Current Ratio 1.42

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AVTX
ROA (LTM) -30.64%
ROE (LTM) -42.52%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AVTX
Debt Ratio Lower is generally better. Negative is bad. 0.79
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.21

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AVTX
Trailing PE 0.07
Forward PE NM
P/S (TTM) 89.32
P/B 3.48
Price/FCF NM
EV/R 2.74
EV/Ebitda NM

FAQs

What is Avalo Therapeutics Inc share price today?

Avalo Therapeutics Inc (AVTX) share price today is $6.87

Can Indians buy Avalo Therapeutics Inc shares?

Yes, Indians can buy shares of Avalo Therapeutics Inc (AVTX) on Vested. To buy Avalo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Avalo Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Avalo Therapeutics Inc (AVTX) via the Vested app. You can start investing in Avalo Therapeutics Inc (AVTX) with a minimum investment of $1.

How to invest in Avalo Therapeutics Inc shares from India?

You can invest in shares of Avalo Therapeutics Inc (AVTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in AVTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Avalo Therapeutics Inc shares
What is Avalo Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Avalo Therapeutics Inc (AVTX) is $22.47. The 52-week low price of Avalo Therapeutics Inc (AVTX) is $3.95.

What is Avalo Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Avalo Therapeutics Inc (AVTX) is 0.0741

What is Avalo Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Avalo Therapeutics Inc (AVTX) is 3.48

What is Avalo Therapeutics Inc dividend yield?

The dividend yield of Avalo Therapeutics Inc (AVTX) is 0.00%

What is the Market Cap of Avalo Therapeutics Inc?

The market capitalization of Avalo Therapeutics Inc (AVTX) is $71.89M

What is Avalo Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Avalo Therapeutics Inc is AVTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top